Cortex Phellodendri total alkaloids ameliorate ulcerative colitis by restoring intestinal barrier integrity via modulation of the ER-mitochondria axis.

What To Know

This abstract reports a preclinical study testing Cortex Phellodendri total alkaloids (CPA) in a DSS mouse model of ulcerative colitis and in DSS‑treated Caco-2 cells. The authors characterized CPA by UPLC‑MS/MS, used proteomics to identify pathways, and validated molecular effects (ER–mitochondria stress signaling, NF‑κB, Claudin‑1, SIRT1/3, OPA1).

They compared whole‑extract effects with two purified alkaloids (berberine and phellodendrine) and describe cooperative interactions.

What the paper reports: CPA reduced experimental colitis and improved markers of intestinal barrier integrity in mice; proteomic and Western blot data point to modulation of ER–mitochondria stress pathways and mitochondrial fitness; the extract showed additive or synergistic effects compared with its two main alkaloids in several molecular readouts.

How to think about this: this is preclinical laboratory research (mouse model and cell lines) and does not demonstrate clinical benefit in people with UC.

The study is useful for researchers and clinicians interested in mechanisms and natural‑product drug discovery, but it should not be taken as evidence to use CPA or its components as a treatment in patients.

Tone and limits: the study supports a mechanistic rationale and identifies potential multi‑target actions of a botanical extract, but human safety, dosing, and efficacy are not addressed here; berberine is a known alkaloid with documented pharmacology, but clinical translation requires trials and safety data.